NCT03638778 - Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

August 17, 2018

Primary Completion Date

December 5, 2018

Study Completion Date

December 5, 2018

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide 3 mg

Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.

DRUG

Semaglutide 7 mg

Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.

DRUG

Semaglutide B 3 mg

Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.

DRUG

Semaglutide B 7 mg

Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.

DRUG

Semaglutide C 3 mg

Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.

DRUG

Semaglutide C 7 mg

Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.

DRUG

Semaglutide D 3 mg

Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.

DRUG

Semaglutide D 7 mg

Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.

Trial Locations (1)

Novo Nordisk Investigational Site, Berlin